At-home Leqembi still requires in-person MRI monitoring for ARIA, which means amyloid-related imaging abnormalities such as brain swelling or tiny bleeds. Patients starting Leqembi, the drug lecanemab, by skin injection in 2026 can ask a specialist how scans, gene testing, and dose pauses will work.
Eisai and Biogen announced on July 13, 2026 that FDA approved Leqembi Iqlik as a starter dose for early Alzheimer's, making lecanemab usable under the skin for the full course. The starter regimen is 500 mg once weekly as two back-to-back 250-mg autoinjector shots, with U.S. launch planned for late August 2026 through specialty pharmacy, according to the Eisai and Biogen approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is eligible to start?
- Why do MRIs still matter when shots move home?
- What should supervision and scan scheduling cover?
- What should ApoE-e4 carriers ask?
Who is eligible to start?
Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid in the brain. That means amyloid testing comes first, along with a baseline MRI and a discussion of ApoE-e4 gene risk.
Ask whether your memory diagnosis, amyloid test result, and baseline scan meet the label. Ask what other health factors could delay a start, such as recent bleeding risk or scan findings. Bring a full medication list and prior MRI reports to that visit.
Why do MRIs still matter when shots move home?
Leqembi carries a boxed warning for ARIA with swelling or fluid, called ARIA-E, and for bleeding-related iron deposits, called ARIA-H. Risk is highest with close watch during the first 14 weeks and first 3 to 6 months, even when ARIA causes no symptoms. FDA added an earlier safety MRI between the second and third infusion on Aug.
28, 2025, to catch swelling sooner, on top of baseline MRI and scans before the 5th, 7th and 14th infusions, according to the FDA safety communication. Ask how your clinic will apply that early-scan approach to a subcutaneous start. At-home dosing does not replace the scan plan.
What should supervision and scan scheduling cover?
Initiation starts under healthcare-provider supervision, and patients still need scheduled safety MRIs with FLAIR and heme-sensitive sequences. Dose interruption rules apply when scans show ARIA findings.
Ask practical questions at the consent visit: Keep MRI appointments even when you feel well. Missing a safety scan can leave silent ARIA unseen.
- Who supervises my first injections and trains my care partner
- Where MRIs are scheduled and which sequences they will use
- What ARIA finding pauses dosing and when dosing can resume
- Who to call day or night for headache, confusion, dizziness, vision change, or gait trouble
What should ApoE-e4 carriers ask?
ApoE-e4 is a gene variant linked to higher ARIA risk. People with two copies, called homozygotes, make up about 15 percent of Alzheimer's patients and face higher rates of symptomatic, serious, and severe ARIA, so FDA labeling calls for ApoE-e4 testing before treatment, according to the FDA package insert summarized by MedLibrary.
Ask whether you have been tested, what your result means for monitoring, and whether your center adjusts scan timing or counseling by result. Ask how test results are recorded and shared with the MRI team. Use the answer to weigh benefit, burden, and travel for scans before you agree to start.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Questions Anti-Amyloid Treatment Patients Can Ask an Alzheimer’s Specialist
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician





